SUPERNUS PHARMACEUTICALS Reports Q2 Earnings Results for FY 2023

August 15, 2023

🌥️Earnings Overview

Supernus Pharmaceuticals ($NASDAQ:SUPN) reported its financial results for the second quarter of 2023 (ending June 30, 2023) on August 8th, 2023. Revenue totaled USD 135.6 million, a 20.3% decrease from the previous year’s second quarter. Net income for the quarter was reported as USD -0.83 million, compared to USD 7.86 million in Q2 FY2022.

Share Price

On Tuesday, SUPERNUS PHARMACEUTICALS reported its earnings results for Q2 of the fiscal year 2023. The stock opened at $32.3 and closed at $32.9, marking an increase of 2.0% from the previous day’s closing price of 32.2. This indicates that investors are confident in the performance of the company in the coming quarter. SUPERNUS PHARMACEUTICALS, a specialty pharmaceutical company focused on neuroscience and related treatments, has seen strong growth in its revenues since the start of the fiscal year. With the release of its Q2 earnings results, the company is likely to continue on this positive trajectory in the coming months. The company’s Q2 earnings report revealed several positive points, including higher revenue and earnings than expected for the quarter.

Additionally, the company’s financial position has strengthened, with a solid balance sheet and improved cash position. This positions SUPERNUS PHARMACEUTICALS for increased profitability and growth in the near term. Overall, SUPERNUS PHARMACEUTICALS’ Q2 earnings results have been positive and provide evidence that the company is well-positioned for further success in the coming months. With a strong financial position and positive earnings results, investors have responded positively to the news and have pushed up the company’s stock price. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Supernus Pharmaceuticals. More…

    Total Revenues Net Income Net Margin
    634.01 43.35 6.6%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Supernus Pharmaceuticals. More…

    Operations Investing Financing
    71.66 169.08 -389.46
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Supernus Pharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    1.29k 373.19 16.89
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Supernus Pharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    14.3% -51.6% 5.1%
    FCF Margin ROE ROA
    11.2% 2.2% 1.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we analyze SUPERNUS PHARMACEUTICALS‘s fundamentals at a granular level to help investors make informed decisions. According to our Star Chart, SUPERNUS PHARMACEUTICALS boasts a high health score of 10/10 when it comes to cashflows and debt, demonstrating that it is capable of paying off debt and funding future operations. Furthermore, it is strong in terms of assets and profitability, medium in terms of growth, and weak in terms of dividends. Based on these criteria, SUPERNUS PHARMACEUTICALS is classified as an ‘elephant’, a type of company that is rich in assets after deducting liabilities. This makes SUPERNUS PHARMACEUTICALS an attractive investment for value investors, who look for companies that have strong underlying fundamentals and are trading at a low valuation. Additionally, dividend investors may be interested in this company to reap the benefits associated with dividends. Overall, SUPERNUS PHARMACEUTICALS is an enticing investment opportunity for value and dividend investors. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company’s competitors include Innopharmax Inc, Evoke Pharma Inc, and Medicamen Biotech Ltd.

    – Innopharmax Inc ($TPEX:4172)

    Innopharmax Inc is a pharmaceutical company with a market cap of 968.22M as of 2022 and a Return on Equity of -12.34%. The company’s main focus is on the development and commercialization of innovative drugs and therapies. Innopharmax has a portfolio of products in various stages of development, including a Phase III clinical trial for its lead product, IPX066, a treatment for Alzheimer’s disease.

    – Evoke Pharma Inc ($NASDAQ:EVOK)

    Evoke Pharma Inc is a pharmaceutical company that specializes in the development of drugs for the treatment of gastrointestinal disorders. The company has a market cap of 5.27M and a return on equity of -103.41%. Evoke Pharma Inc is a publicly traded company on the Nasdaq exchange under the ticker symbol EVOK.

    – Medicamen Biotech Ltd ($BSE:531146)

    With a market cap of 11.67B as of 2022, Medicamen Biotech Ltd has a ROE of 8.45%. The company focuses on the research, development, and commercialization of novel therapeutics for the treatment of cancer and other diseases.


    Investors should take note of the decreased revenue for SUPERNUS PHARMACEUTICALS in the second quarter of FY 2023, as total revenue decreased by 20.3% compared to the same period in the previous year. Net income remained in the negative, at USD -0.83 million, which was significantly lower than the USD 7.86 million reported in the same quarter of FY2022. Given this financial performance, investors should contemplate carefully before investing in SUPERNUS PHARMACEUTICALS.

    Recent Posts

    Leave a Comment